New tools to interrogate endocannabinoid signalling :: from natural compounds to synthetic drugs /
New Tools to Interrogate Endocannabinoid Signalling comprehensively covers the innovative research into both natural and synthetic compounds. This timely volume will be a valuable resource to pharmaceutical researchers and medicinal chemists working in natural products and endocannabinoid drug disco...
Gespeichert in:
| Weitere Verfasser: | |
|---|---|
| Format: | Elektronisch E-Book |
| Sprache: | English |
| Veröffentlicht: |
Cambridge :
Royal Society of Chemistry,
2020.
|
| Schriftenreihe: | RSC drug discovery series ;
76. |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Zusammenfassung: | New Tools to Interrogate Endocannabinoid Signalling comprehensively covers the innovative research into both natural and synthetic compounds. This timely volume will be a valuable resource to pharmaceutical researchers and medicinal chemists working in natural products and endocannabinoid drug discovery in academia and industry. |
| Beschreibung: | 1 online resource (458 pages) |
| ISBN: | 1839160853 9781839160851 9781839160752 1839160756 |
Internformat
MARC
| LEADER | 00000cam a2200000 i 4500 | ||
|---|---|---|---|
| 001 | ZDB-4-EBA-on1206395701 | ||
| 003 | OCoLC | ||
| 005 | 20241004212047.0 | ||
| 006 | m o d | ||
| 007 | cr cnu---unuuu | ||
| 008 | 201114s2020 enk ob 001 0 eng d | ||
| 040 | |a EBLCP |b eng |e pn |c EBLCP |d N$T |d UKAHL |d OCLCO |d EBLCP |d YDX |d OCLCF |d UKMGB |d OCLCO |d OCLCQ |d OCLCO |d K6U |d OCLCQ |d OCLCO |d OCLCL | ||
| 015 | |a GBC0E4357 |2 bnb | ||
| 016 | 7 | |a 019950204 |2 Uk | |
| 019 | |a 1204343101 | ||
| 020 | |a 1839160853 |q (electronic bk.) | ||
| 020 | |a 9781839160851 |q (electronic bk.) | ||
| 020 | |a 9781839160752 |q (PDF ebook) | ||
| 020 | |a 1839160756 | ||
| 020 | |z 178801801X | ||
| 020 | |z 9781788018012 | ||
| 035 | |a (OCoLC)1206395701 |z (OCoLC)1204343101 | ||
| 037 | |a 3-178-9781839160851 |b Ingram Content Group | ||
| 050 | 4 | |a RM666.C266 | |
| 060 | 4 | |a QV 77.7 | |
| 082 | 7 | |a 615.7827 |2 23 | |
| 049 | |a MAIN | ||
| 245 | 0 | 0 | |a New tools to interrogate endocannabinoid signalling : |b from natural compounds to synthetic drugs / |c edited by Mauro Maccarrone. |
| 260 | |a Cambridge : |b Royal Society of Chemistry, |c 2020. | ||
| 300 | |a 1 online resource (458 pages) | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 490 | 1 | |a RSC drug discovery series ; |v 76 | |
| 588 | 0 | |a Online resource; title from PDF title page (EBSCO, viewed November 19, 2020). | |
| 588 | 0 | |a Print version record. | |
| 505 | 0 | |a Intro -- Title -- Copyright -- Contents -- Chapter 1 Quest for Magic Bullets to Solve the Endocannabinoid Puzzle -- 1.1 Introduction -- 1.2 The Complex Endocannabinoid System -- 1.3 The Challenge of Designing Effective Drugs -- Acknowledgements -- References -- Chapter 2 Phytocannabinoids Versus Endocannabinoids. A Modern View of the Endocannabinoid System -- 2.1 From the Cannabis Plant to the Identification of the Endocannabinoid System -- 2.2 Overview of the Endocannabinoid Signaling System -- 2.2.1 Cannabinoid Receptors -- 2.2.2 Endocannabinoid Ligands -- 2.2.3 Endocannabinoid Synthesis | |
| 505 | 8 | |a 2.2.4 Endocannabinoid Inactivation -- 2.2.5 Endocannabinoids as Precursors of Novel Signaling Lipids -- 2.3 Conclusions and Future Perspectives -- References -- Chapter 3 Natural Compounds and Synthetic Drugs to Target Type-1 Cannabinoid (CB1) Receptor -- 3.1 Introduction -- 3.2 Phytocannabinoids and Classical/Non-classical and Other Analogues -- 3.2.1 Phytocannabinoids -- 3.2.2 Classical Cannabinoids -- 3.2.3 Non-classical Cannabinoids and Other Analogues -- 3.2.4 Other Approaches in Classical Cannabinoids -- 3.3 Endocannabinoids and Endogenous-like Analogues | |
| 505 | 8 | |a 3.3.1 Endogenous-like Derivatives with Enhanced Metabolic Stability -- 3.3.2 Hybrid Endocannabinoid Probes -- 3.3.3 Other Endocannabinoid Probes -- 3.4 Miscellaneous Synthetic Cannabinoids -- 3.5 Neutral Antagonists and Inverse Agonists -- 3.6 Allosteric Modulators -- 3.7 Conclusions -- Acknowledgements -- References -- Chapter 4 Natural Compounds and Synthetic Drugs to Target Type-2 Cannabinoid (CB2) Receptor -- 4.1 Cannabinoid Receptor Type-2 -- 4.2 CB2R Ligands -- 4.2.1 Endogenous Cannabinoids and Related Fatty Acid Derivatives -- 4.2.2 Phytocannabinoids -- 4.2.3 Synthetic Cannabinoids | |
| 505 | 8 | |a 4.2.4 Clinically Evaluated CB2R Agonists -- 4.2.5 Allosteric Ligands -- 4.2.6 Summary -- 4.3 Structural Biology and Structural Elucidation of CB2R -- 4.4 Chemical CB2R Probes -- 4.4.1 Radioligands and PET Tracers -- 4.4.2 Fluorescently Labeled Ligands -- 4.4.3 Covalent and Photoaffinity Probes -- 4.5 Conclusions and Outlook -- Abbreviations -- Dedication -- Acknowledgements -- References -- Chapter 5 Natural and Synthetic Cannabinoids Targeting Non-CB1, Non-CB2 G Protein-coupled Receptors -- 5.1 Introduction -- 5.2 GPR55 -- 5.2.1 General Features -- 5.2.2 Biological Relevance | |
| 505 | 8 | |a 5.2.3 Cannabinoids Targeting GPR55 -- 5.3 GPR18 -- 5.3.1 General Features -- 5.3.2 Biological Relevance -- 5.3.3 Cannabinoids Targeting GPR18 -- 5.4 GPR3/6/12 -- 5.4.1 General Features -- 5.4.2 Biological Relevance -- 5.4.3 Cannabinoids Targeting GPR3/6/12 -- 5.5 Other GPCRs Related to Cannabinoids -- 5.5.1 Well-established GPCRs -- 5.5.2 Orphan or Recently Deorphanized Receptors -- 5.6 Conclusions -- Acknowledgements -- References -- Chapter 6 Natural Compounds and Synthetic Drugs Targeting the Ionotropic Cannabinoid Members of Transient Receptor Potential (TRP) Channels -- 6.1 Introduction -- 6.2 TRPV Channels. | |
| 520 | |a New Tools to Interrogate Endocannabinoid Signalling comprehensively covers the innovative research into both natural and synthetic compounds. This timely volume will be a valuable resource to pharmaceutical researchers and medicinal chemists working in natural products and endocannabinoid drug discovery in academia and industry. | ||
| 650 | 0 | |a Cannabinoids |x Therapeutic use. | |
| 650 | 0 | |a Cellular signal transduction. |0 http://id.loc.gov/authorities/subjects/sh89002397 | |
| 650 | 2 | |a Endocannabinoids |x therapeutic use |0 https://id.nlm.nih.gov/mesh/D063388Q000627 | |
| 650 | 2 | |a Signal Transduction |0 https://id.nlm.nih.gov/mesh/D015398 | |
| 650 | 6 | |a Cannabinoïdes |x Emploi en thérapeutique. | |
| 650 | 6 | |a Transduction du signal cellulaire. | |
| 650 | 7 | |a Cannabinoids |x Therapeutic use |2 fast | |
| 650 | 7 | |a Cellular signal transduction |2 fast | |
| 700 | 1 | |a Maccarrone, Mauro, |d 1962- |1 https://id.oclc.org/worldcat/entity/E39PBJdmjTGPrxHPJjJffGF9Xd |0 http://id.loc.gov/authorities/names/nb2016013833 | |
| 758 | |i has work: |a New tools to interrogate endocannabinoid signalling (Text) |1 https://id.oclc.org/worldcat/entity/E39PCG3MqYP3x3bRRtKTkDgKr3 |4 https://id.oclc.org/worldcat/ontology/hasWork | ||
| 776 | 0 | 8 | |i Print version: |a Maccarrone, Mauro. |t New Tools to Interrogate Endocannabinoid Signalling : From Natural Compounds to Synthetic Drugs. |d Cambridge : Royal Society of Chemistry, ©2020 |z 9781788018012 |
| 830 | 0 | |a RSC drug discovery series ; |v 76. |0 http://id.loc.gov/authorities/names/no2010092643 | |
| 856 | 4 | 0 | |l FWS01 |p ZDB-4-EBA |q FWS_PDA_EBA |u https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=2668240 |3 Volltext |
| 938 | |a YBP Library Services |b YANK |n 21020314 | ||
| 938 | |a Askews and Holts Library Services |b ASKH |n AH37278535 | ||
| 938 | |a Askews and Holts Library Services |b ASKH |n AH37278762 | ||
| 938 | |a ProQuest Ebook Central |b EBLB |n EBL6386208 | ||
| 938 | |a EBSCOhost |b EBSC |n 2668240 | ||
| 938 | |a YBP Library Services |b YANK |n 301731249 | ||
| 994 | |a 92 |b GEBAY | ||
| 912 | |a ZDB-4-EBA | ||
| 049 | |a DE-863 | ||
Datensatz im Suchindex
| DE-BY-FWS_katkey | ZDB-4-EBA-on1206395701 |
|---|---|
| _version_ | 1816882533005000704 |
| adam_text | |
| any_adam_object | |
| author2 | Maccarrone, Mauro, 1962- |
| author2_role | |
| author2_variant | m m mm |
| author_GND | http://id.loc.gov/authorities/names/nb2016013833 |
| author_facet | Maccarrone, Mauro, 1962- |
| author_sort | Maccarrone, Mauro, 1962- |
| building | Verbundindex |
| bvnumber | localFWS |
| callnumber-first | R - Medicine |
| callnumber-label | RM666 |
| callnumber-raw | RM666.C266 |
| callnumber-search | RM666.C266 |
| callnumber-sort | RM 3666 C266 |
| callnumber-subject | RM - Therapeutics and Pharmacology |
| collection | ZDB-4-EBA |
| contents | Intro -- Title -- Copyright -- Contents -- Chapter 1 Quest for Magic Bullets to Solve the Endocannabinoid Puzzle -- 1.1 Introduction -- 1.2 The Complex Endocannabinoid System -- 1.3 The Challenge of Designing Effective Drugs -- Acknowledgements -- References -- Chapter 2 Phytocannabinoids Versus Endocannabinoids. A Modern View of the Endocannabinoid System -- 2.1 From the Cannabis Plant to the Identification of the Endocannabinoid System -- 2.2 Overview of the Endocannabinoid Signaling System -- 2.2.1 Cannabinoid Receptors -- 2.2.2 Endocannabinoid Ligands -- 2.2.3 Endocannabinoid Synthesis 2.2.4 Endocannabinoid Inactivation -- 2.2.5 Endocannabinoids as Precursors of Novel Signaling Lipids -- 2.3 Conclusions and Future Perspectives -- References -- Chapter 3 Natural Compounds and Synthetic Drugs to Target Type-1 Cannabinoid (CB1) Receptor -- 3.1 Introduction -- 3.2 Phytocannabinoids and Classical/Non-classical and Other Analogues -- 3.2.1 Phytocannabinoids -- 3.2.2 Classical Cannabinoids -- 3.2.3 Non-classical Cannabinoids and Other Analogues -- 3.2.4 Other Approaches in Classical Cannabinoids -- 3.3 Endocannabinoids and Endogenous-like Analogues 3.3.1 Endogenous-like Derivatives with Enhanced Metabolic Stability -- 3.3.2 Hybrid Endocannabinoid Probes -- 3.3.3 Other Endocannabinoid Probes -- 3.4 Miscellaneous Synthetic Cannabinoids -- 3.5 Neutral Antagonists and Inverse Agonists -- 3.6 Allosteric Modulators -- 3.7 Conclusions -- Acknowledgements -- References -- Chapter 4 Natural Compounds and Synthetic Drugs to Target Type-2 Cannabinoid (CB2) Receptor -- 4.1 Cannabinoid Receptor Type-2 -- 4.2 CB2R Ligands -- 4.2.1 Endogenous Cannabinoids and Related Fatty Acid Derivatives -- 4.2.2 Phytocannabinoids -- 4.2.3 Synthetic Cannabinoids 4.2.4 Clinically Evaluated CB2R Agonists -- 4.2.5 Allosteric Ligands -- 4.2.6 Summary -- 4.3 Structural Biology and Structural Elucidation of CB2R -- 4.4 Chemical CB2R Probes -- 4.4.1 Radioligands and PET Tracers -- 4.4.2 Fluorescently Labeled Ligands -- 4.4.3 Covalent and Photoaffinity Probes -- 4.5 Conclusions and Outlook -- Abbreviations -- Dedication -- Acknowledgements -- References -- Chapter 5 Natural and Synthetic Cannabinoids Targeting Non-CB1, Non-CB2 G Protein-coupled Receptors -- 5.1 Introduction -- 5.2 GPR55 -- 5.2.1 General Features -- 5.2.2 Biological Relevance 5.2.3 Cannabinoids Targeting GPR55 -- 5.3 GPR18 -- 5.3.1 General Features -- 5.3.2 Biological Relevance -- 5.3.3 Cannabinoids Targeting GPR18 -- 5.4 GPR3/6/12 -- 5.4.1 General Features -- 5.4.2 Biological Relevance -- 5.4.3 Cannabinoids Targeting GPR3/6/12 -- 5.5 Other GPCRs Related to Cannabinoids -- 5.5.1 Well-established GPCRs -- 5.5.2 Orphan or Recently Deorphanized Receptors -- 5.6 Conclusions -- Acknowledgements -- References -- Chapter 6 Natural Compounds and Synthetic Drugs Targeting the Ionotropic Cannabinoid Members of Transient Receptor Potential (TRP) Channels -- 6.1 Introduction -- 6.2 TRPV Channels. |
| ctrlnum | (OCoLC)1206395701 |
| dewey-full | 615.7827 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 615 - Pharmacology and therapeutics |
| dewey-raw | 615.7827 |
| dewey-search | 615.7827 |
| dewey-sort | 3615.7827 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>06463cam a2200709 i 4500</leader><controlfield tag="001">ZDB-4-EBA-on1206395701</controlfield><controlfield tag="003">OCoLC</controlfield><controlfield tag="005">20241004212047.0</controlfield><controlfield tag="006">m o d </controlfield><controlfield tag="007">cr cnu---unuuu</controlfield><controlfield tag="008">201114s2020 enk ob 001 0 eng d</controlfield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">EBLCP</subfield><subfield code="b">eng</subfield><subfield code="e">pn</subfield><subfield code="c">EBLCP</subfield><subfield code="d">N$T</subfield><subfield code="d">UKAHL</subfield><subfield code="d">OCLCO</subfield><subfield code="d">EBLCP</subfield><subfield code="d">YDX</subfield><subfield code="d">OCLCF</subfield><subfield code="d">UKMGB</subfield><subfield code="d">OCLCO</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">OCLCO</subfield><subfield code="d">K6U</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">OCLCO</subfield><subfield code="d">OCLCL</subfield></datafield><datafield tag="015" ind1=" " ind2=" "><subfield code="a">GBC0E4357</subfield><subfield code="2">bnb</subfield></datafield><datafield tag="016" ind1="7" ind2=" "><subfield code="a">019950204</subfield><subfield code="2">Uk</subfield></datafield><datafield tag="019" ind1=" " ind2=" "><subfield code="a">1204343101</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">1839160853</subfield><subfield code="q">(electronic bk.)</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781839160851</subfield><subfield code="q">(electronic bk.)</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781839160752</subfield><subfield code="q">(PDF ebook)</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">1839160756</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="z">178801801X</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="z">9781788018012</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)1206395701</subfield><subfield code="z">(OCoLC)1204343101</subfield></datafield><datafield tag="037" ind1=" " ind2=" "><subfield code="a">3-178-9781839160851</subfield><subfield code="b">Ingram Content Group</subfield></datafield><datafield tag="050" ind1=" " ind2="4"><subfield code="a">RM666.C266</subfield></datafield><datafield tag="060" ind1=" " ind2="4"><subfield code="a">QV 77.7</subfield></datafield><datafield tag="082" ind1="7" ind2=" "><subfield code="a">615.7827</subfield><subfield code="2">23</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">MAIN</subfield></datafield><datafield tag="245" ind1="0" ind2="0"><subfield code="a">New tools to interrogate endocannabinoid signalling :</subfield><subfield code="b">from natural compounds to synthetic drugs /</subfield><subfield code="c">edited by Mauro Maccarrone.</subfield></datafield><datafield tag="260" ind1=" " ind2=" "><subfield code="a">Cambridge :</subfield><subfield code="b">Royal Society of Chemistry,</subfield><subfield code="c">2020.</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 online resource (458 pages)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="1" ind2=" "><subfield code="a">RSC drug discovery series ;</subfield><subfield code="v">76</subfield></datafield><datafield tag="588" ind1="0" ind2=" "><subfield code="a">Online resource; title from PDF title page (EBSCO, viewed November 19, 2020).</subfield></datafield><datafield tag="588" ind1="0" ind2=" "><subfield code="a">Print version record.</subfield></datafield><datafield tag="505" ind1="0" ind2=" "><subfield code="a">Intro -- Title -- Copyright -- Contents -- Chapter 1 Quest for Magic Bullets to Solve the Endocannabinoid Puzzle -- 1.1 Introduction -- 1.2 The Complex Endocannabinoid System -- 1.3 The Challenge of Designing Effective Drugs -- Acknowledgements -- References -- Chapter 2 Phytocannabinoids Versus Endocannabinoids. A Modern View of the Endocannabinoid System -- 2.1 From the Cannabis Plant to the Identification of the Endocannabinoid System -- 2.2 Overview of the Endocannabinoid Signaling System -- 2.2.1 Cannabinoid Receptors -- 2.2.2 Endocannabinoid Ligands -- 2.2.3 Endocannabinoid Synthesis</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">2.2.4 Endocannabinoid Inactivation -- 2.2.5 Endocannabinoids as Precursors of Novel Signaling Lipids -- 2.3 Conclusions and Future Perspectives -- References -- Chapter 3 Natural Compounds and Synthetic Drugs to Target Type-1 Cannabinoid (CB1) Receptor -- 3.1 Introduction -- 3.2 Phytocannabinoids and Classical/Non-classical and Other Analogues -- 3.2.1 Phytocannabinoids -- 3.2.2 Classical Cannabinoids -- 3.2.3 Non-classical Cannabinoids and Other Analogues -- 3.2.4 Other Approaches in Classical Cannabinoids -- 3.3 Endocannabinoids and Endogenous-like Analogues</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">3.3.1 Endogenous-like Derivatives with Enhanced Metabolic Stability -- 3.3.2 Hybrid Endocannabinoid Probes -- 3.3.3 Other Endocannabinoid Probes -- 3.4 Miscellaneous Synthetic Cannabinoids -- 3.5 Neutral Antagonists and Inverse Agonists -- 3.6 Allosteric Modulators -- 3.7 Conclusions -- Acknowledgements -- References -- Chapter 4 Natural Compounds and Synthetic Drugs to Target Type-2 Cannabinoid (CB2) Receptor -- 4.1 Cannabinoid Receptor Type-2 -- 4.2 CB2R Ligands -- 4.2.1 Endogenous Cannabinoids and Related Fatty Acid Derivatives -- 4.2.2 Phytocannabinoids -- 4.2.3 Synthetic Cannabinoids</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">4.2.4 Clinically Evaluated CB2R Agonists -- 4.2.5 Allosteric Ligands -- 4.2.6 Summary -- 4.3 Structural Biology and Structural Elucidation of CB2R -- 4.4 Chemical CB2R Probes -- 4.4.1 Radioligands and PET Tracers -- 4.4.2 Fluorescently Labeled Ligands -- 4.4.3 Covalent and Photoaffinity Probes -- 4.5 Conclusions and Outlook -- Abbreviations -- Dedication -- Acknowledgements -- References -- Chapter 5 Natural and Synthetic Cannabinoids Targeting Non-CB1, Non-CB2 G Protein-coupled Receptors -- 5.1 Introduction -- 5.2 GPR55 -- 5.2.1 General Features -- 5.2.2 Biological Relevance</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">5.2.3 Cannabinoids Targeting GPR55 -- 5.3 GPR18 -- 5.3.1 General Features -- 5.3.2 Biological Relevance -- 5.3.3 Cannabinoids Targeting GPR18 -- 5.4 GPR3/6/12 -- 5.4.1 General Features -- 5.4.2 Biological Relevance -- 5.4.3 Cannabinoids Targeting GPR3/6/12 -- 5.5 Other GPCRs Related to Cannabinoids -- 5.5.1 Well-established GPCRs -- 5.5.2 Orphan or Recently Deorphanized Receptors -- 5.6 Conclusions -- Acknowledgements -- References -- Chapter 6 Natural Compounds and Synthetic Drugs Targeting the Ionotropic Cannabinoid Members of Transient Receptor Potential (TRP) Channels -- 6.1 Introduction -- 6.2 TRPV Channels.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">New Tools to Interrogate Endocannabinoid Signalling comprehensively covers the innovative research into both natural and synthetic compounds. This timely volume will be a valuable resource to pharmaceutical researchers and medicinal chemists working in natural products and endocannabinoid drug discovery in academia and industry.</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Cannabinoids</subfield><subfield code="x">Therapeutic use.</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Cellular signal transduction.</subfield><subfield code="0">http://id.loc.gov/authorities/subjects/sh89002397</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Endocannabinoids</subfield><subfield code="x">therapeutic use</subfield><subfield code="0">https://id.nlm.nih.gov/mesh/D063388Q000627</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Signal Transduction</subfield><subfield code="0">https://id.nlm.nih.gov/mesh/D015398</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Cannabinoïdes</subfield><subfield code="x">Emploi en thérapeutique.</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Transduction du signal cellulaire.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Cannabinoids</subfield><subfield code="x">Therapeutic use</subfield><subfield code="2">fast</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Cellular signal transduction</subfield><subfield code="2">fast</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Maccarrone, Mauro,</subfield><subfield code="d">1962-</subfield><subfield code="1">https://id.oclc.org/worldcat/entity/E39PBJdmjTGPrxHPJjJffGF9Xd</subfield><subfield code="0">http://id.loc.gov/authorities/names/nb2016013833</subfield></datafield><datafield tag="758" ind1=" " ind2=" "><subfield code="i">has work:</subfield><subfield code="a">New tools to interrogate endocannabinoid signalling (Text)</subfield><subfield code="1">https://id.oclc.org/worldcat/entity/E39PCG3MqYP3x3bRRtKTkDgKr3</subfield><subfield code="4">https://id.oclc.org/worldcat/ontology/hasWork</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Print version:</subfield><subfield code="a">Maccarrone, Mauro.</subfield><subfield code="t">New Tools to Interrogate Endocannabinoid Signalling : From Natural Compounds to Synthetic Drugs.</subfield><subfield code="d">Cambridge : Royal Society of Chemistry, ©2020</subfield><subfield code="z">9781788018012</subfield></datafield><datafield tag="830" ind1=" " ind2="0"><subfield code="a">RSC drug discovery series ;</subfield><subfield code="v">76.</subfield><subfield code="0">http://id.loc.gov/authorities/names/no2010092643</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="l">FWS01</subfield><subfield code="p">ZDB-4-EBA</subfield><subfield code="q">FWS_PDA_EBA</subfield><subfield code="u">https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=2668240</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">YBP Library Services</subfield><subfield code="b">YANK</subfield><subfield code="n">21020314</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">Askews and Holts Library Services</subfield><subfield code="b">ASKH</subfield><subfield code="n">AH37278535</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">Askews and Holts Library Services</subfield><subfield code="b">ASKH</subfield><subfield code="n">AH37278762</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">ProQuest Ebook Central</subfield><subfield code="b">EBLB</subfield><subfield code="n">EBL6386208</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">EBSCOhost</subfield><subfield code="b">EBSC</subfield><subfield code="n">2668240</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">YBP Library Services</subfield><subfield code="b">YANK</subfield><subfield code="n">301731249</subfield></datafield><datafield tag="994" ind1=" " ind2=" "><subfield code="a">92</subfield><subfield code="b">GEBAY</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-4-EBA</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-863</subfield></datafield></record></collection> |
| id | ZDB-4-EBA-on1206395701 |
| illustrated | Not Illustrated |
| indexdate | 2024-11-27T13:30:07Z |
| institution | BVB |
| isbn | 1839160853 9781839160851 9781839160752 1839160756 |
| language | English |
| oclc_num | 1206395701 |
| open_access_boolean | |
| owner | MAIN DE-863 DE-BY-FWS |
| owner_facet | MAIN DE-863 DE-BY-FWS |
| physical | 1 online resource (458 pages) |
| psigel | ZDB-4-EBA |
| publishDate | 2020 |
| publishDateSearch | 2020 |
| publishDateSort | 2020 |
| publisher | Royal Society of Chemistry, |
| record_format | marc |
| series | RSC drug discovery series ; |
| series2 | RSC drug discovery series ; |
| spelling | New tools to interrogate endocannabinoid signalling : from natural compounds to synthetic drugs / edited by Mauro Maccarrone. Cambridge : Royal Society of Chemistry, 2020. 1 online resource (458 pages) text txt rdacontent computer c rdamedia online resource cr rdacarrier RSC drug discovery series ; 76 Online resource; title from PDF title page (EBSCO, viewed November 19, 2020). Print version record. Intro -- Title -- Copyright -- Contents -- Chapter 1 Quest for Magic Bullets to Solve the Endocannabinoid Puzzle -- 1.1 Introduction -- 1.2 The Complex Endocannabinoid System -- 1.3 The Challenge of Designing Effective Drugs -- Acknowledgements -- References -- Chapter 2 Phytocannabinoids Versus Endocannabinoids. A Modern View of the Endocannabinoid System -- 2.1 From the Cannabis Plant to the Identification of the Endocannabinoid System -- 2.2 Overview of the Endocannabinoid Signaling System -- 2.2.1 Cannabinoid Receptors -- 2.2.2 Endocannabinoid Ligands -- 2.2.3 Endocannabinoid Synthesis 2.2.4 Endocannabinoid Inactivation -- 2.2.5 Endocannabinoids as Precursors of Novel Signaling Lipids -- 2.3 Conclusions and Future Perspectives -- References -- Chapter 3 Natural Compounds and Synthetic Drugs to Target Type-1 Cannabinoid (CB1) Receptor -- 3.1 Introduction -- 3.2 Phytocannabinoids and Classical/Non-classical and Other Analogues -- 3.2.1 Phytocannabinoids -- 3.2.2 Classical Cannabinoids -- 3.2.3 Non-classical Cannabinoids and Other Analogues -- 3.2.4 Other Approaches in Classical Cannabinoids -- 3.3 Endocannabinoids and Endogenous-like Analogues 3.3.1 Endogenous-like Derivatives with Enhanced Metabolic Stability -- 3.3.2 Hybrid Endocannabinoid Probes -- 3.3.3 Other Endocannabinoid Probes -- 3.4 Miscellaneous Synthetic Cannabinoids -- 3.5 Neutral Antagonists and Inverse Agonists -- 3.6 Allosteric Modulators -- 3.7 Conclusions -- Acknowledgements -- References -- Chapter 4 Natural Compounds and Synthetic Drugs to Target Type-2 Cannabinoid (CB2) Receptor -- 4.1 Cannabinoid Receptor Type-2 -- 4.2 CB2R Ligands -- 4.2.1 Endogenous Cannabinoids and Related Fatty Acid Derivatives -- 4.2.2 Phytocannabinoids -- 4.2.3 Synthetic Cannabinoids 4.2.4 Clinically Evaluated CB2R Agonists -- 4.2.5 Allosteric Ligands -- 4.2.6 Summary -- 4.3 Structural Biology and Structural Elucidation of CB2R -- 4.4 Chemical CB2R Probes -- 4.4.1 Radioligands and PET Tracers -- 4.4.2 Fluorescently Labeled Ligands -- 4.4.3 Covalent and Photoaffinity Probes -- 4.5 Conclusions and Outlook -- Abbreviations -- Dedication -- Acknowledgements -- References -- Chapter 5 Natural and Synthetic Cannabinoids Targeting Non-CB1, Non-CB2 G Protein-coupled Receptors -- 5.1 Introduction -- 5.2 GPR55 -- 5.2.1 General Features -- 5.2.2 Biological Relevance 5.2.3 Cannabinoids Targeting GPR55 -- 5.3 GPR18 -- 5.3.1 General Features -- 5.3.2 Biological Relevance -- 5.3.3 Cannabinoids Targeting GPR18 -- 5.4 GPR3/6/12 -- 5.4.1 General Features -- 5.4.2 Biological Relevance -- 5.4.3 Cannabinoids Targeting GPR3/6/12 -- 5.5 Other GPCRs Related to Cannabinoids -- 5.5.1 Well-established GPCRs -- 5.5.2 Orphan or Recently Deorphanized Receptors -- 5.6 Conclusions -- Acknowledgements -- References -- Chapter 6 Natural Compounds and Synthetic Drugs Targeting the Ionotropic Cannabinoid Members of Transient Receptor Potential (TRP) Channels -- 6.1 Introduction -- 6.2 TRPV Channels. New Tools to Interrogate Endocannabinoid Signalling comprehensively covers the innovative research into both natural and synthetic compounds. This timely volume will be a valuable resource to pharmaceutical researchers and medicinal chemists working in natural products and endocannabinoid drug discovery in academia and industry. Cannabinoids Therapeutic use. Cellular signal transduction. http://id.loc.gov/authorities/subjects/sh89002397 Endocannabinoids therapeutic use https://id.nlm.nih.gov/mesh/D063388Q000627 Signal Transduction https://id.nlm.nih.gov/mesh/D015398 Cannabinoïdes Emploi en thérapeutique. Transduction du signal cellulaire. Cannabinoids Therapeutic use fast Cellular signal transduction fast Maccarrone, Mauro, 1962- https://id.oclc.org/worldcat/entity/E39PBJdmjTGPrxHPJjJffGF9Xd http://id.loc.gov/authorities/names/nb2016013833 has work: New tools to interrogate endocannabinoid signalling (Text) https://id.oclc.org/worldcat/entity/E39PCG3MqYP3x3bRRtKTkDgKr3 https://id.oclc.org/worldcat/ontology/hasWork Print version: Maccarrone, Mauro. New Tools to Interrogate Endocannabinoid Signalling : From Natural Compounds to Synthetic Drugs. Cambridge : Royal Society of Chemistry, ©2020 9781788018012 RSC drug discovery series ; 76. http://id.loc.gov/authorities/names/no2010092643 FWS01 ZDB-4-EBA FWS_PDA_EBA https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=2668240 Volltext |
| spellingShingle | New tools to interrogate endocannabinoid signalling : from natural compounds to synthetic drugs / RSC drug discovery series ; Intro -- Title -- Copyright -- Contents -- Chapter 1 Quest for Magic Bullets to Solve the Endocannabinoid Puzzle -- 1.1 Introduction -- 1.2 The Complex Endocannabinoid System -- 1.3 The Challenge of Designing Effective Drugs -- Acknowledgements -- References -- Chapter 2 Phytocannabinoids Versus Endocannabinoids. A Modern View of the Endocannabinoid System -- 2.1 From the Cannabis Plant to the Identification of the Endocannabinoid System -- 2.2 Overview of the Endocannabinoid Signaling System -- 2.2.1 Cannabinoid Receptors -- 2.2.2 Endocannabinoid Ligands -- 2.2.3 Endocannabinoid Synthesis 2.2.4 Endocannabinoid Inactivation -- 2.2.5 Endocannabinoids as Precursors of Novel Signaling Lipids -- 2.3 Conclusions and Future Perspectives -- References -- Chapter 3 Natural Compounds and Synthetic Drugs to Target Type-1 Cannabinoid (CB1) Receptor -- 3.1 Introduction -- 3.2 Phytocannabinoids and Classical/Non-classical and Other Analogues -- 3.2.1 Phytocannabinoids -- 3.2.2 Classical Cannabinoids -- 3.2.3 Non-classical Cannabinoids and Other Analogues -- 3.2.4 Other Approaches in Classical Cannabinoids -- 3.3 Endocannabinoids and Endogenous-like Analogues 3.3.1 Endogenous-like Derivatives with Enhanced Metabolic Stability -- 3.3.2 Hybrid Endocannabinoid Probes -- 3.3.3 Other Endocannabinoid Probes -- 3.4 Miscellaneous Synthetic Cannabinoids -- 3.5 Neutral Antagonists and Inverse Agonists -- 3.6 Allosteric Modulators -- 3.7 Conclusions -- Acknowledgements -- References -- Chapter 4 Natural Compounds and Synthetic Drugs to Target Type-2 Cannabinoid (CB2) Receptor -- 4.1 Cannabinoid Receptor Type-2 -- 4.2 CB2R Ligands -- 4.2.1 Endogenous Cannabinoids and Related Fatty Acid Derivatives -- 4.2.2 Phytocannabinoids -- 4.2.3 Synthetic Cannabinoids 4.2.4 Clinically Evaluated CB2R Agonists -- 4.2.5 Allosteric Ligands -- 4.2.6 Summary -- 4.3 Structural Biology and Structural Elucidation of CB2R -- 4.4 Chemical CB2R Probes -- 4.4.1 Radioligands and PET Tracers -- 4.4.2 Fluorescently Labeled Ligands -- 4.4.3 Covalent and Photoaffinity Probes -- 4.5 Conclusions and Outlook -- Abbreviations -- Dedication -- Acknowledgements -- References -- Chapter 5 Natural and Synthetic Cannabinoids Targeting Non-CB1, Non-CB2 G Protein-coupled Receptors -- 5.1 Introduction -- 5.2 GPR55 -- 5.2.1 General Features -- 5.2.2 Biological Relevance 5.2.3 Cannabinoids Targeting GPR55 -- 5.3 GPR18 -- 5.3.1 General Features -- 5.3.2 Biological Relevance -- 5.3.3 Cannabinoids Targeting GPR18 -- 5.4 GPR3/6/12 -- 5.4.1 General Features -- 5.4.2 Biological Relevance -- 5.4.3 Cannabinoids Targeting GPR3/6/12 -- 5.5 Other GPCRs Related to Cannabinoids -- 5.5.1 Well-established GPCRs -- 5.5.2 Orphan or Recently Deorphanized Receptors -- 5.6 Conclusions -- Acknowledgements -- References -- Chapter 6 Natural Compounds and Synthetic Drugs Targeting the Ionotropic Cannabinoid Members of Transient Receptor Potential (TRP) Channels -- 6.1 Introduction -- 6.2 TRPV Channels. Cannabinoids Therapeutic use. Cellular signal transduction. http://id.loc.gov/authorities/subjects/sh89002397 Endocannabinoids therapeutic use https://id.nlm.nih.gov/mesh/D063388Q000627 Signal Transduction https://id.nlm.nih.gov/mesh/D015398 Cannabinoïdes Emploi en thérapeutique. Transduction du signal cellulaire. Cannabinoids Therapeutic use fast Cellular signal transduction fast |
| subject_GND | http://id.loc.gov/authorities/subjects/sh89002397 https://id.nlm.nih.gov/mesh/D063388Q000627 https://id.nlm.nih.gov/mesh/D015398 |
| title | New tools to interrogate endocannabinoid signalling : from natural compounds to synthetic drugs / |
| title_auth | New tools to interrogate endocannabinoid signalling : from natural compounds to synthetic drugs / |
| title_exact_search | New tools to interrogate endocannabinoid signalling : from natural compounds to synthetic drugs / |
| title_full | New tools to interrogate endocannabinoid signalling : from natural compounds to synthetic drugs / edited by Mauro Maccarrone. |
| title_fullStr | New tools to interrogate endocannabinoid signalling : from natural compounds to synthetic drugs / edited by Mauro Maccarrone. |
| title_full_unstemmed | New tools to interrogate endocannabinoid signalling : from natural compounds to synthetic drugs / edited by Mauro Maccarrone. |
| title_short | New tools to interrogate endocannabinoid signalling : |
| title_sort | new tools to interrogate endocannabinoid signalling from natural compounds to synthetic drugs |
| title_sub | from natural compounds to synthetic drugs / |
| topic | Cannabinoids Therapeutic use. Cellular signal transduction. http://id.loc.gov/authorities/subjects/sh89002397 Endocannabinoids therapeutic use https://id.nlm.nih.gov/mesh/D063388Q000627 Signal Transduction https://id.nlm.nih.gov/mesh/D015398 Cannabinoïdes Emploi en thérapeutique. Transduction du signal cellulaire. Cannabinoids Therapeutic use fast Cellular signal transduction fast |
| topic_facet | Cannabinoids Therapeutic use. Cellular signal transduction. Endocannabinoids therapeutic use Signal Transduction Cannabinoïdes Emploi en thérapeutique. Transduction du signal cellulaire. Cannabinoids Therapeutic use Cellular signal transduction |
| url | https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=2668240 |
| work_keys_str_mv | AT maccarronemauro newtoolstointerrogateendocannabinoidsignallingfromnaturalcompoundstosyntheticdrugs |